The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
Open accessAbstract
Background: ‘No evidence of disease activity’ (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression (‘NEDA-3’), is used as a comprehensive measure of treatment response in relapsing multiple sclerosis (RMS), but is weighted towards inflammatory activity. Accelerated brain volume loss (BVL) occurs in RMS and is an objective measure of disease worsening and progression. Objective: To assess the contribution of individual components of NEDA-3 and the impact of adding BVL to NEDA-3 (‘NEDA-4’) Methods: We analysed data pooled from two placebo-controlled phase 3 fingolimod trials in RMS and assessed NEDA-4 using different annual BVL mean rate thresholds (0.2%–1.2%). Results: At 2 years, 31.0% (217/700) of patients receiving fingolimod 0.5 mg achieved NEDA-3 versus 9.9% (71/715) on placebo (odds ratio (OR) 4.07; p < 0.0001). Adding BVL (threshold of 0.4%), the respective proportions of patients achieving NEDA-4 were 19.7% (139/706) and 5.3% (38/721; OR 4.41; p < 0.0001). NEDA-4 status favoured fingolimod across all BVL thresholds tested (OR 4.01–4.41; p < 0.0001). Conclusion: NEDA-4 has the potential to capture the impact of therapies on both inflammation and neurodegeneration, and deserves further evaluation across different compounds and in long-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Self-citationAssociation between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Self-citationHavrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Eight-year follow-up study of brain atrophy in patients with MS
Fisher, E., Rudick, R. A., Simon, J. H., Cutter, G., Baier, M., Lee, J. C., Miller, D., Weinstock-Guttman, B., Mass, M. K., Dougherty, D. S., et al. (2002) · Neurology · doi:10.1212/01.wnl.0000036271.49066.06 · Cited by 374
Brain atrophy and lesion load predict long term disability in multiple sclerosis
Popescu, V., Agosta, F., Hulst, H. E., Sluimer, I. C., Knol, D. L., Sormani, M. P., Enzinger, C., Ropele, S., Alonso, J., Sastre-Garriga, J., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304094 · Cited by 331
Self-citationPathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 301
Self-citationSormani, M. P., Arnold, D. L., & De Stefano, N. (2014) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 297
Self-citationEstablishing pathological cut-offs of brain atrophy rates in multiple sclerosis
De Stefano, N., Stromillo, M. L., Giorgio, A., Bartolozzi, M. L., Battaglini, M., Baldini, M., Portaccio, E., Amato, M. P., & Sormani, M. P. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309903 · Cited by 256
Self-citationGiovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators (2013) · Annals of Neurology · doi:10.1002/ana.23863 · Cited by 203
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
MRI predictors of cognitive outcome in early multiple sclerosis
Deloire, M. S. A., Ruet, A., Lamargue-Hamel, D., Bonnet, M., Dousset, V., & Brochet, B. (2011) · Neurology · doi:10.1212/wnl.0b013e318212a8be · Cited by 145
Bevan, C. J., & Cree, B. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5486 · Cited by 144
Self-citationCorrelation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Radue, E. W., Barkhof, F., Kappos, L., Sprenger, T., Häring, D. A., de Vera, A., von Rosenstiel, P., Bright, J. R., Francis, G., & Cohen, J. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001281 · Cited by 144
Self-citationRadue, E. W., O'Connor, P., Polman, C. H., Hohlfeld, R., Calabresi, P., Selmaj, K., Mueller-Lenke, N., Agoropoulou, C., Holdbrook, F., de Vera, A., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1051 · Cited by 115
Self-citationHoráková, D., Dwyer, M. G., Havrdová, E., Cox, J. L., Doležal, O., Bergsland, N., Rimes, B., Seidl, Z., Vaněčková, M., & Zivadinov, R. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.12.005 · Cited by 108
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
Prosperini, L., Giannì, C., Leonardi, L., Giglio, L. D., Borriello, G., Galgani, S., Pozzilli, C., & Gasperini, C. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511417481 · Cited by 95
Nixon, R., Bergvall, N., Tomic, D., Sfikas, N., Cutter, G., & Giovannoni, G. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0167-z · Cited by 91
Self-citationLiu, C., & Blumhardt, L. D. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.450 · Cited by 86
Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis
Rudick, R. A., Lee, J.-C., Cutter, G., Miller, D. M., BOURDETTE, D. N., Weinstock‐Guttman, B., Hyde, R., Zhang, H., & You, X. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.150 · Cited by 78
Editors' welcome and a working definition for a multiple sclerosis cure
Banwell, B., Giovannoni, G., Hawkes, C. H., & LUBLIN, F. D. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.12.001 · Cited by 78
Fingolimod effect on brain volume loss independently contributes to its effect on disability
Sormani, M. P., Stefano, N. D., Francis, G. S., Sprenger, T., Chin, P., Radue, E. W., & Kappos, L. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515569099 · Cited by 33
Self-citation
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Self-citationLong‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationReaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Self-citation
Metadata
- Authors
- Kappos, L., De Stefano, N., Freedman, M. S., Cree, B. A., Radue, E.-W., Sprenger, T., Sormani, M. P., Smith, T., Häring, D. A., Piani Meier, D., & Tomic, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2016-07-19
- Volume
- 22
- Issue
- 10
- Pages
- 1297-1305
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2173315418
- Cited by
- 289
- References
- 29
- FWCI
- 34.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.